Recurrent breast carcinoma presenting as postmenopausal vaginal bleeding: A case report  by Binstock, Anna et al.
Gynecologic Oncology Reports 10 (2014) 38–40
Contents lists available at ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /gynorCase ReportRecurrent breast carcinoma presenting as postmenopausal vaginal
bleeding: A case reportAnna Binstock a, Ashlee L. Smith b, Alexander B. Olawaiye b,⁎
a Division of Obstetrics and Gynecology, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States
b Division of Gynecologic Oncology, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States⁎ Corresponding author at: Division of Gynecologic Onc
Gynecology and Reproductive Sciences, University of P
Magee-Womens Hospital of UPMC, 300 Halket Stree
Tel: +14126415468; fax: +14126415417.
E-mail addresses: binstockab@upmc.edu (A. Binstoc
(A.B. Olawaiye).
http://dx.doi.org/10.1016/j.gynor.2013.06.003
2211-338X/© 2014 The Authors. Published by Elseviera r t i c l e i n f o bleeding and was subsequently diagnosed with breast cancer metas-Article history:
Received 18 March 2013
Accepted 15 June 2013






tases to the endometrium.
Case
A 43 yo G1P0010 presented to her primary gynecologist with
postmenopausal vaginal bleeding. At age 35, she was diagnosed
with Stage IIA cancer of the right breast and underwent a segmental
mastectomy with sentinel lymph node dissection. Pathology was
consistent with an inﬁltrating ductal carcinoma measuring 3.3 cm,
ER/PR+ and Her-2 Neu-. Margins were positive for disease and sheand right breast radiation. She initially recurred 3 years following herIntroduction
Metastases to the female genital tract from extra-genital primaries
are rare, with the most common sites affected being the vagina and
ovaries (Mazur et al., 1984). Uterine metastases account for approxi-
mately 4% of genital tract metastases, with 47% of cases involving the
breast as the primary site (Mazur et al., 1984; Kumar and Hart, 1982).
In addition, most genital tract metastases are asymptomatic, and are
found incidentally or on autopsy. While there have been several
case reports of metastases from the breast to the uterus, involvement
of the endometrium by such metastases is extremely rare. A PubMed
search of the terms “breast carcinoma”, “metastases”, and “endome-
trium” revealed that most symptomatic metastases were diagnosed
in the setting of post menopausal vaginal bleeding. The search also
yielded a unique case in which the patient presented with abdominal
pain, distension, and a pelvic ultrasound signiﬁcant for diffuse thick-
ening of the uterus (Arslan et al., 2013). Most cases in which the
endometrium is involved present with vaginal bleeding, whereas
myometrial involvement tends to be asymptomatic. Herein, we re-
view a case in which a post-menopausal female on Tamoxifen with
an established diagnosis of breast cancer presented with vaginalology, Department of Obstetrics,
ittsburgh School of Medicine,
t, Pittsburgh, PA 15213, USA.
k), olawaiyea@mail.magee.edu
Inc. This is an open access article ununderwent re-excision. She was treated with adjuvant chemotherapy
initial diagnosis with biopsy proven bony metastases in the left pubic
symphysis. A bone scan identiﬁed innumerable bony metastases in
the skull, ribs, spine, and pelvis and a PET scan revealed metastases
to the liver. She was treated with zoledronic acid and chemotherapy.
Two years following her initial recurrence, she was diagnosed with
another recurrence, and was found to have right-sided breast cancer
and multi-focal left-sided breast cancer with the largest tumor mea-
suring 5.5 cm. Pathology was consistent with her primary cancer
(Fig. 1). She underwent a bilateral mastectomy with reconstruction
followed by adjuvant chemotherapy and Tamoxifen. Following her
treatment, the patient had stable, but extensive bony metastases in
her neck, chest, abdomen, and pelvis.
Approximately 7 years after her initial diagnosis and 2 years fol-
lowing her bilateral mastectomy, she underwent a routine PET scan
which revealed decreasing bony metastases and no other evidence
of disease. One month after this PET scan, she reported a two month
history of scant vaginal bleeding to her gynecologist. She endorsed
menopause at 38 yo with no prior episodes of postmenopausal vagi-
nal bleeding. A transvaginal ultrasound revealed a uterus measuring
1.7 × 3 × 5.7 cm with a 1.2 cm posterior leiomyoma and a 3 mm en-
dometrial lining. Endometrial biopsy conﬁrmed adenocarcinoma of
breast origin, consistent with her primary tumor. She was referred to
Gynecologic Oncology for evaluation and surgical management. She was
treated with 6 cycles of paclitaxel and underwent a robotic-assisted
total laparoscopic hysterectomy with bilateral salpingo-oophorectomy
approximately 5 months after her diagnosis. Intraoperative ﬁndings
were signiﬁcant for a uterus that appeared to be normal in size with nod-
ular appearing lesions present on the uterine serosa,malignant appearing
lesions present on the surface of bilateral ovaries, and miliary lesions in
the posterior cul-de-sac. There were no other areas in the abdomender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Pathologic specimen frommulti-focal breast cancer recurrence in 2008; invasive
ductal carcinoma, ﬁxed in buffered formalin and stained with hematoxylin and eosin.
Fig. 3. Pathologic specimen from robotic-assisted total laparoscopic hysterectomy with
bilateral salpingo-oophorectomy (3/2011); uterus with lymphovascular space invasion,
stained with hematoxylin and eosin.
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tal carcinoma located on bilateral ovaries, fallopian tubes, uterine serosa,
myometrium, endometrium, and endocervical stroma. Lymphovascular
space invasion and perineural invasion were present (Figs. 2, 3, 4, 5). Im-
munohistochemical staining was weakly ER positive, PR negative, and
Her-2 Neu negative. The sample was strongly positive for Ki-67, consis-
tent with primary breast adenocarcinoma.
Postoperatively, her course was complicated by an obstructing
gallstone requiring ERCP, SIADH, and abdominal ascites secondary
to progressive liver metastases. She passed away from progression
of her primary disease 5 months following her surgery.
Discussion
Metastases to the genital tract from extra-genital cancers are ex-
ceedingly rare. However, the most common origins of metastases to
the genital tract are the gastrointestinal tract and the breast. A review
by Piura et al. revealed that 56% of primary extra-genital cancers that
metastasize to the uterus originate from the breast, most commonly
lobular carcinomas (Piura et al., 1999; LeBouedec et al., 1991). When
the genital tract is affected, the ovaries are the reproductive site mostFig. 2. Pathologic specimen from robotic-assisted total laparoscopic hysterectomy with
bilateral salpingo-oophorectomy (3/2011); fallopian tubewith invasive ductal carcinoma
and lymphovascular space invasion, stained with hematoxylin and eosin.commonly involved. Any patient with abnormal vaginal bleeding
should be evaluated for vaginal, cervical, and uterine pathology. As
this case aptly demonstrates, negative imaging should not reduce the
concern for pathology or alter the work-up of a patient with abnormal
symptoms.
Tamoxifen is a common adjuvant therapy in the treatment of
hormone-receptor positive breast cancer, and is known to increase
the risk of simple endometrial hyperplasia, complex atypical hyper-
plasia, and endometrioid adenocarcinoma, and therefore can result
in abnormal uterine bleeding. In patients with primary breast cancer
maintained on Tamoxifen, there are few reported cases of uterine me-
tastases (Piura et al., 1999; Maymon et al., 1996; Famoriyo et al.,
2004). This case illustrates the importance of obtaining a rapid path-
ologic diagnosis, as treatment of Tamoxifen-induced endometrial pa-
thology and uterine metastases are very different (Ben-Baruch et al.,
1990). In cases of a primary uterine disease induced by Tamoxifen,
surgical intervention with hysterectomy, with or without bilateral
salpingoophorectomy is often sufﬁcient for treatment (Ben-Baruch
et al., 1990). However, in cases of uterine metastases, there is also a
role for systemic adjuvant therapy. Often, at the time of diagnosis of
uterine metastases there is widespread disease.
There is a paucity of data regarding the best way to manage such
cases. As mentioned, once widespread metastases from the primary
breast cancer are conﬁrmed, there is no foreseeable beneﬁt from hys-
terectomy outside of symptom control, namely control of vaginal
bleeding and compressive symptoms. This case demonstrates the rapid-
ity with which patient's primary disease progressed despite surgical re-
section of uterine disease and appropriately timed chemotherapy.
Interestingly, a PET scan done prior to her gynecologic surgery re-
vealed no areas of increased uptake in either the ovaries or the uterus.
This ﬁnding may be explained by the fact that FDG uptake is weaker
in ductal carcinomas than in lobular carcinomas (Hara et al., 2010).
However, the patient did have numerous other bony lesions that
were evident on PET. In addition, several cases of incidental uptake
in the uterus and ovaries in metastatic breast cancer have been re-
ported (Groheux et al., 2013). As previously mentioned, the patient's
transvaginal ultrasound was also unremarkable. In one reported case
of uterine metastases, the patient had a thickened endometrial lining,
measuring 11 mm, with no CT ﬁndings (Piura et al., 1999). Most cases
in the literature present with vaginal bleeding and are diagnosed with
endometrial biopsy. Rare cases of incidental imaging ﬁndings have
been reported, but are not typical (Groheux et al., 2013). Because
uterine metastases from primary breast cancer are rare, there is little
40 A. Binstock et al. / Gynecologic Oncology Reports 10 (2014) 38–40data available to support which imaging modality is most effective in
diagnosis. If imaging is absolutely necessary to assess uterine disease,
an enhanced pelvic MRI may be a reasonable choice.
We reviewed a case of a 43 yo female with metastatic breast car-
cinoma presenting as postmenopausal bleeding while on Tamoxifen.
Despite unremarkable pelvic imaging ﬁndings, prompt evaluation of
her postmenopausal bleeding led to the timely diagnosis of her recur-
rence and initiation of treatment. Ultimately the patient succumbed
to her primary disease. This case demonstrates the importance of
maintaining a broad differential diagnosis in the patient with post-
menopausal bleeding in the setting of a history of breast cancer and
Tamoxifen use. Imaging alone is not sufﬁcient for a diagnosis, and
may be misleading. Evaluation of symptoms with a tissue biopsy re-
mains essential in identifying the underlying pathology.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.gynor.2013.06.003.
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